Aptose Biosciences (TSE:APS) Share Price Crosses Above 50-Day Moving Average – What’s Next?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s share price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$2.19 and traded as high as C$2.26. Aptose Biosciences shares last traded at C$2.26, with a volume of 781 shares traded.

Analysts Set New Price Targets

Separately, Alliance Global Partners cut shares of Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Aptose Biosciences has an average rating of “Hold”.

Aptose Biosciences Stock Performance

The company has a quick ratio of 5.41, a current ratio of 1.05 and a debt-to-equity ratio of -117.37. The stock has a market capitalization of C$5.77 million, a P/E ratio of 3.28 and a beta of -0.46. The business has a fifty day moving average price of C$2.19 and a 200-day moving average price of C$1.94.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last issued its earnings results on Thursday, November 13th. The biotechnology company reported C($2.01) earnings per share for the quarter. On average, sell-side analysts expect that Aptose Biosciences Inc. will post -0.59 EPS for the current year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.